Form 4: Mirum Pharmaceuticals Executive Peter Radovich Acquires Stock Options and Restricted Stock Units

Peter Radovich, President and COO of Mirum Pharmaceuticals, acquired stock options and restricted stock units on January 21, 2025, according to a recent SEC filing.

Summary

• Peter Radovich, the President and COO of Mirum Pharmaceuticals, was granted stock options for 50,000 shares at an exercise price of $47.98 on January 21, 2025.
• These options vest over a period starting one year after January 21, 2025, with 1/4 vesting initially and the remainder in 36 equal monthly installments.
• Radovich also received 12,500 restricted stock units (RSUs) which vest in three equal annual installments starting January 21, 2025.
• Additionally, 21,660 performance-based restricted stock units (PSUs) vested on January 21, 2025, with 2/3 vesting on March 15, 2025, and the remaining 1/3 on March 15, 2026.

Sentiment

Score: 7

Explanation: The document reflects standard executive compensation practices, which is generally positive for aligning management with shareholder interests. The vesting of performance-based units suggests the company is meeting its goals.

Positives

• The vesting of performance-based restricted stock units indicates that performance goals were met, which is a positive sign for the company.
• The grant of stock options and restricted stock units aligns the executive's interests with those of the shareholders.

Industry Context

This type of equity-based compensation is common in the pharmaceutical industry to incentivize executives and align their interests with the long-term success of the company.

Comparison to Industry Standards

• Equity grants are a standard practice for executive compensation in the biotech and pharmaceutical industries.
• The vesting schedules described are typical, with stock options vesting over several years and restricted stock units often vesting annually or over a few years.
• Performance-based equity awards are also common, linking executive compensation to the achievement of specific company goals, similar to other companies such as BioMarin Pharmaceutical and Vertex Pharmaceuticals.

Stakeholder Impact

• The equity grants align the executive's interests with those of shareholders, potentially leading to increased focus on long-term value creation.
• Employees may view the vesting of performance-based units as a positive sign of the company's progress.

Key Dates

Keywords

stock options, restricted stock units, performance stock units, executive compensation, insider trading, SEC Form 4, Mirum Pharmaceuticals, equity awards, vesting